Dermatologic drug reactions

被引:31
作者
McKenna, JK [1 ]
Leiferman, KM [1 ]
机构
[1] Univ Utah, Sch Med 4B454, Dept Dermatol, Salt Lake City, UT 84132 USA
关键词
D O I
10.1016/j.iac.2004.03.007
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Adverse reactions to medications are estimated to occur in 0.1% to 1% of patients using systemic medications. Certain medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics, and anticonvulsants, have drug eruption rates approaching 1% to 5% [1]. Approximately 30 drug-related cutaneous reaction patterns are described (Box 1) [2]. In addition, the same medication may evoke a different reaction pattern in different individuals. This fact makes identification of the offending agent difficult for primary care physicians, allergists, and dermatologists. An estimated 2% of medication-related skin eruptions meet the World Health Organization definition of a serious reaction [3]. Of these reactions, several constitute truly life-threatening emergencies and need rapid accurate diagnosis and intervention. This review describes common, serious, and distinctive drug reaction patterns in skin. The pathogenesis of drug allergy is discussed with respect to immunologic mechanisms; nonimmunologic drug reactions may also occur. Basic classification of skin lesions is reviewed; however, this discussion centers on identification of the most common or serious cutaneous reaction patterns.
引用
收藏
页码:399 / +
页数:26
相关论文
共 70 条
[1]   Angiotensin II receptor blocker-associated angioedema: On the heels of ACE inhibitor angioedema [J].
Abdi, R ;
Dong, VM ;
Lee, CJ ;
Ntoso, KA .
PHARMACOTHERAPY, 2002, 22 (09) :1173-1175
[2]   RATES OF CUTANEOUS REACTIONS TO DRUGS - REPORT FROM BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM [J].
ARNDT, KA ;
JICK, H .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1976, 235 (09) :918-923
[3]   Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis - Results of an international prospective study [J].
Auquier-Dunant, A ;
Mockenhaupt, M ;
Naldi, L ;
Correia, O ;
Schroder, W ;
Roujeau, JC .
ARCHIVES OF DERMATOLOGY, 2002, 138 (08) :1019-1024
[4]   Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis - A prospective noncomparative study showing no benefit on mortality or progression [J].
Bachot, N ;
Revuz, J ;
Roujeau, JC .
ARCHIVES OF DERMATOLOGY, 2003, 139 (01) :33-36
[5]   SCORTEN: A severity-of-illness score for toxic epidermal necrolysis [J].
Bastuji-Garin, S ;
Fouchard, N ;
Bertocchi, M ;
Roujeau, JC ;
Revuz, J ;
Wolkenstein, P .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 115 (02) :149-153
[6]   Acute generalized exanthematous pustulosis [J].
Beylot, C ;
Doutre, MS ;
BeylotBarry, M .
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 1996, 15 (04) :244-249
[7]  
Bigby M, 2001, ARCH DERMATOL, V137, P765
[8]  
Bircher AJ, 1999, EUR J DERMATOL, V9, P657
[9]  
Bonkovsy HL, 2001, J AM ACAD DERMATOL, V44, P159, DOI 10.1067/mjd.2001.109311
[10]   Recognition of pemphigus antigens in drug-induced pemphigus vulgaris and pemphigus foliaceus [J].
Brenner, S ;
BialyGolan, A ;
Anhalt, GJ .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1997, 36 (06) :919-923